StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
21
This year
1
Publishing Date
2024 - 03 - 08
1
2023 - 05 - 16
1
2023 - 02 - 28
1
2023 - 02 - 02
1
2022 - 12 - 08
2
2022 - 04 - 26
1
2022 - 03 - 24
1
2022 - 03 - 15
1
2022 - 02 - 18
1
2022 - 01 - 12
1
2021 - 11 - 12
1
2021 - 10 - 25
1
2021 - 09 - 30
1
2021 - 07 - 29
1
2021 - 07 - 06
1
2021 - 06 - 30
1
2021 - 06 - 23
1
2021 - 06 - 03
1
2021 - 04 - 28
1
2021 - 01 - 25
1
Sector
Health technology
21
Tags
Acquire
1
Alliances
2
Als
4
Asco
1
Asia
1
Biotech-beach
30
Breakthrough therapy
1
Candidate
1
Care
1
Cell carcinoma
1
China
1
Chronic hepatitis b
1
Clearance
8
Clinical-trials-phase-i
1
Clinical-trials-phase-ii
17
Clinical-trials-phase-iii
3
Commercialization
1
Conference
7
Covid
1
Covid-19
1
Day
4
Designation
2
Disease
8
Drug
1
Earnings
9
Enroll
1
Events
11
Expected
1
Fast track designation
1
Fda
2
Fibrosis
3
First
1
Genetic
1
Global
3
Hereditary angioedema
2
Hzn-457
2
Liver
6
Liver disease
2
Market
10
Media
2
Milestone
4
N/a
13
Nash
2
Payment
3
Pharmaceuticals
29
Phase 1
14
Phase 2
17
Phase 2b
8
Phase 3
4
Pipeline
3
Positive
2
Report
2
Research
17
Results
24
Study
13
Therapeutics
5
Topline
2
Treatment
21
Trial
3
Year
3
Entities
3m company
20
Abbott laboratories
57
Abbvie inc.
117
Accuray incorporated
18
Adamis pharmaceuticals corporation
19
Adial pharmaceuticals, inc
18
Alnylam pharmaceuticals, inc.
38
Amgen inc.
46
Arcutis biotherapeutics, inc.
24
Arrowhead pharmaceuticals, inc.
21
Astellas pharma inc
50
Astrazeneca plc
46
Bausch health companies inc.
35
Biogen inc.
41
Bioxcel therapeutics, inc.
19
Boston scientific corporation
21
Brainsway ltd.
39
Bridgebio pharma, inc.
18
Bristol-myers squibb company
93
Cns pharmaceuticals, inc.
26
Coherus biosciences, inc.
28
Ecolab inc.
47
Eli lilly and company
175
Fortress biotech, inc.
27
Gilead sciences, inc.
50
Glaxosmithkline plc
98
Horizon therapeutics public limited company
19
Hoth therapeutics, inc.
24
Incyte corporation
77
Intellia therapeutics, inc.
31
Ionis pharmaceuticals, inc.
19
Johnson & johnson
198
Karyopharm therapeutics inc.
27
Koninklijke philips n.v.
20
Medicinova, inc.
24
Medtronic plc
44
Merck & company, inc.
63
Moleculin biotech, inc.
28
Novartis ag
137
Novo nordisk a/s
34
Nrx pharmaceuticals inc
19
Orange
84
Perrigo company
19
Pfizer, inc.
74
Reata pharmaceuticals, inc.
28
Regeneron pharmaceuticals, inc.
57
Regenxbio inc.
25
Sanofi
279
Soligenix, inc.
19
Sorrento therapeutics, inc.
37
Takeda pharmaceutical company limited
50
Teleflex incorporated
19
Teva pharmaceutical industries ltd
76
Tg therapeutics, inc.
24
Tonix pharmaceuticals holding corp.
29
Ultragenyx pharmaceutical inc.
25
Verrica pharmaceuticals inc.
23
Vertex pharmaceuticals incorporated
27
Viatris inc.
45
Xylem inc.
35
Symbols
ARWR
21
HZNP
2
TAK
3
Exchanges
Nasdaq
21
Nyse
3
Crawled Date
2024 - 03 - 08
1
2023 - 05 - 16
1
2023 - 02 - 28
1
2023 - 02 - 02
1
2022 - 12 - 08
2
2022 - 04 - 26
1
2022 - 03 - 24
1
2022 - 03 - 15
1
2022 - 02 - 18
1
2022 - 01 - 12
1
2021 - 11 - 12
1
2021 - 10 - 25
1
2021 - 09 - 30
1
2021 - 07 - 29
1
2021 - 07 - 06
1
2021 - 06 - 30
1
2021 - 06 - 23
1
2021 - 06 - 03
1
2021 - 04 - 28
1
2021 - 01 - 25
1
Crawled Time
12:00
5
12:15
1
12:20
1
12:30
1
13:00
7
13:30
1
14:00
3
14:30
1
20:00
1
Source
www.biospace.com
21
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Treatment
entities :
Arrowhead pharmaceuticals, inc.
save search
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
Published:
2024-03-08
(Crawled : 14:30)
- biospace.com/
ARWR
|
$24.25
1.38%
380K
|
Health Technology
|
-27.95%
|
O:
1.14%
H:
5.63%
C:
-0.39%
treatment
pharmaceuticals
study
Arrowhead Pharmaceuticals Completes Enrollment of Phase 3 PALISADE Clinical Trial Evaluating ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome
Published:
2023-05-16
(Crawled : 12:00)
- biospace.com/
ARWR
|
$24.25
1.38%
380K
|
Health Technology
|
-40.04%
|
O:
-1.33%
H:
0.05%
C:
-4.37%
treatment
pharmaceuticals
trial
Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
Published:
2023-02-28
(Crawled : 14:00)
- biospace.com/
ARWR
|
$24.25
1.38%
380K
|
Health Technology
|
-26.63%
|
O:
-0.46%
H:
2.06%
C:
-0.46%
treatment
ongoing
study
phase 1
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis
Published:
2023-02-02
(Crawled : 13:00)
- biospace.com/
ARWR
|
$24.25
1.38%
380K
|
Health Technology
|
-32.22%
|
O:
1.3%
H:
3.52%
C:
3.52%
treatment
fibrosis
pharmaceuticals
study
phase 1
Arrowhead Announces First Patient Enrolled in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
Published:
2022-12-08
(Crawled : 14:00)
- biospace.com/
HZNP
|
$116.3
0.03%
29M
|
Health Technology
|
20.77%
|
O:
0.26%
H:
2.62%
C:
0.37%
ARWR
|
$24.25
1.38%
380K
|
Health Technology
|
-27.21%
|
O:
0.85%
H:
0.6%
C:
-4.77%
hzn-457
treatment
trial
phase 1
Horizon Therapeutics plc Announces First Subject Dosed in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
Published:
2022-12-08
(Crawled : 14:00)
- biospace.com/
HZNP
|
$116.3
0.03%
29M
|
Health Technology
|
20.77%
|
O:
0.26%
H:
2.62%
C:
0.37%
ARWR
|
$24.25
1.38%
380K
|
Health Technology
|
-27.21%
|
O:
0.85%
H:
0.6%
C:
-4.77%
hzn-457
treatment
trial
therapeutics
phase 1
Arrowhead Pharmaceuticals Initiates Phase 2 GATEWAY Study of Investigational ARO-ANG3 for Treatment of Homozygous Familial Hypercholesterolemia
Published:
2022-04-26
(Crawled : 12:20)
- biospace.com/
ARWR
|
$24.25
1.38%
380K
|
Health Technology
|
-44.03%
|
O:
0.89%
H:
0.0%
C:
0.0%
treatment
phase 2
hypercholesterolemia
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MUC5AC for Treatment of Muco-Obstructive Lung Diseases
Published:
2022-03-24
(Crawled : 12:00)
- biospace.com/
ARWR
|
$24.25
1.38%
380K
|
Health Technology
|
-47.52%
|
O:
0.9%
H:
2.48%
C:
2.44%
treatment
clearance
phase 1
disease
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma
Published:
2022-03-15
(Crawled : 12:30)
- biospace.com/
ARWR
|
$24.25
1.38%
380K
|
Health Technology
|
-39.63%
|
O:
1.89%
H:
2.65%
C:
0.87%
treatment
clearance
phase 1
phase 2
Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
Published:
2022-02-18
(Crawled : 13:00)
- biospace.com/
ARWR
|
$24.25
1.38%
380K
|
Health Technology
|
-47.06%
|
O:
-0.09%
H:
2.1%
C:
-1.97%
treatment
als
disease
media
phase 1
phase 2
phase 3
Arrowhead Pharmaceuticals Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome
Published:
2022-01-12
(Crawled : 13:30)
- biospace.com/
ARWR
|
$24.25
1.38%
380K
|
Health Technology
|
-59.81%
|
O:
1.71%
H:
1.17%
C:
-3.83%
phase 3
syndros
treatment
Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment at AASLD Liver Meeting
Published:
2021-11-12
(Crawled : 13:00)
- biospace.com/
TAK
|
News
|
$13.38
0.15%
1.3M
|
Health Technology
|
-6.15%
|
O:
0.74%
H:
0.0%
C:
0.0%
ARWR
|
$24.25
1.38%
380K
|
Health Technology
|
-68.96%
|
O:
-1.54%
H:
0.0%
C:
0.0%
treatment
liver
Arrowhead Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-C3 for Treatment of Complement Mediated Diseases
Published:
2021-10-25
(Crawled : 12:00)
- biospace.com/
ARWR
|
$24.25
1.38%
380K
|
Health Technology
|
-63.89%
|
O:
-0.69%
H:
1.61%
C:
0.11%
disease
media
treatment
phase 1
phase 2
clearance
Arrowhead Pharmaceuticals Initiates Phase 2b Study of ARO-APOC3 for Treatment of Mixed Dyslipidemia
Published:
2021-09-30
(Crawled : 12:00)
- biospace.com/
ARWR
|
$24.25
1.38%
380K
|
Health Technology
|
-60.55%
|
O:
1.24%
H:
3.54%
C:
1.71%
treatment
phase 2
phase 2b
Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Associated Liver Disease
Published:
2021-07-29
(Crawled : 20:00)
- biospace.com/
TAK
|
News
|
$13.38
0.15%
1.3M
|
Health Technology
|
-22.01%
|
O:
0.0%
H:
0.06%
C:
-1.17%
ARWR
|
$24.25
1.38%
380K
|
Health Technology
|
-65.01%
|
O:
1.95%
H:
1.82%
C:
-1.98%
disease
liver disease
treatment
fda
therapy
breakthrough therapy
liver
designation
Arrowhead Announces Positive Interim Results from Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
Published:
2021-07-06
(Crawled : 13:00)
- biospace.com/
ARWR
|
$24.25
1.38%
380K
|
Health Technology
|
-64.38%
|
O:
-3.19%
H:
3.74%
C:
-2.98%
treatment
phase 1
renal
positive
results
phase 1b
phase 2b
cell carcinoma
Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia
Published:
2021-06-30
(Crawled : 13:00)
- biospace.com/
ARWR
|
$24.25
1.38%
380K
|
Health Technology
|
-70.65%
|
O:
-0.6%
H:
4.07%
C:
2.23%
treatment
phase 2
phase 2b
Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress
Published:
2021-06-23
(Crawled : 12:00)
- biospace.com/
ARWR
|
$24.25
1.38%
380K
|
Health Technology
|
-73.07%
|
O:
1.32%
H:
4.07%
C:
-2.12%
treatment
positive
nash
liver
Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia
Published:
2021-06-03
(Crawled : 12:15)
- biospace.com/
ARWR
|
$24.25
1.38%
380K
|
Health Technology
|
-66.89%
|
O:
0.18%
H:
0.65%
C:
0.21%
treatment
phase 2
phase 2b
Arrowhead Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver Disease
Published:
2021-04-28
(Crawled : 13:00)
- biospace.com/
TAK
|
News
|
$13.38
0.15%
1.3M
|
Health Technology
|
-20.76%
|
O:
-0.95%
H:
0.84%
C:
0.48%
ARWR
|
$24.25
1.38%
380K
|
Health Technology
|
-67.9%
|
O:
0.01%
H:
2.92%
C:
1.92%
disease
liver disease
treatment
fibrosis
liver
← Previous
1
2
Next →
Gainers vs Losers
85%
15%
Top 10 Gainers
MTTR
|
News
M
|
$4.56
162.07%
21M
|
AGBA
|
$2.99
139.2%
64M
|
Finance
CZOO
|
$8.67
73.75%
23M
|
EDBL
|
News
|
$6.47
72.07%
1.9M
|
MTC
|
$2.21
41.67%
5.6M
|
Technology Services
OPRT
|
News
|
$3.12
38.67%
11M
|
Finance
PALI
|
$6.59
33.67%
23M
|
Manufacturing
VNRX
|
$0.7989
33.15%
3.2M
|
Health Technology
BTCM
|
$3.51
30.0%
730K
|
Arts, Entertainment, and Recrea...
MLEC
|
$1.81
29.29%
2.8M
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.